Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Related Keywords

,Optimizing Care Across ,Prostate Cancer ,World Study ,Optimizing Outcomes ,Prostate Cancer Treatment ,Prostate Cancer News ,Prostate Cancer Updates ,Prostate Cancer Therapies ,Prostate Cancer Management ,Prostate Cancer Year In Review ,Prostate Cancer Year In Review 2023 ,